MarketCapExport financials
Maravai LifeSciences Holdings (MRVI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Maravai LifeSciences Holdings Income Statement 2025-2011 | MRVI
Brief overview of profit and loss at Maravai LifeSciences Holdings
The conclusions below are based on five years of reported results. The revenue attributed to Maravai LifeSciences Holdings moved from $284 million to $186 million between the two endpoints. Across the full period, sales moved by −34.6%; the average annual rate was −8.1%. Revenue ended the period on a sustained downward trend.
The five-year change in gross profit reached −83.4%: from $204 million to $34 million. Costs absorbed a larger share of revenue over the period. The gross margin was 72% at the start and 18.3% at the end. Weakening gross profitability reduces the quality of the top-line trend.
The five-year EBITDA result moved by −252.8%: from 125 million dollars to −192 million dollars. EBITDA underperformed the top-line trend. EBITDA margin was 44.2% at the start and −103.2% at the end. The business retained less EBITDA from each unit of revenue.
The net financial result changed from $89 million to −$131 million. Profit turned into a loss, the most concerning signal in the results.
The five-year change in capitalization reached −14.7%: from $361 million to $307 million. The negative valuation trend points to increased investor caution.
What the figures show
The current trajectory does not yet confirm a sustainable recovery. The most visible risks are weaker operating efficiency, a weaker final result and a lower gross margin. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Maravai LifeSciences Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
307 M | 1.21 B | 1.01 B | 1.93 B | 3.32 B | 361 M | - | - | - | - | - | - | - | - | - |
Shares |
144 M | 138 M | 132 M | 132 M | 115 M | 10.4 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
2.13 | 8.75 | 7.69 | 14.7 | 28.9 | 34.8 | - | - | - | - | - | - | - | - | - |
Net Income |
-131 M | -145 M | -138 M | 491 M | 182 M | 89 M | -4.47 M | -4.47 M | - | - | - | - | - | - | - |
Revenue |
186 M | 259 M | 289 M | 883 M | 799 M | 284 M | 143 M | 124 M | - | - | - | - | - | - | - |
Cost of Revenue |
152 M | 151 M | 149 M | 169 M | 141 M | 79.6 M | 66.8 M | - | - | - | - | - | - | - | - |
Gross Profit |
34 M | 108 M | 140 M | - | - | - | 76.3 M | 63.1 M | - | - | - | - | - | - | - |
Operating Income |
-215 M | -236 M | -31.6 M | 574 M | 555 M | 120 M | 24 M | - | - | - | - | - | - | - | - |
Interest Expense |
-4.15 M | -2.34 M | 45.9 M | 20.4 M | 30.3 M | 30.7 M | 30 M | - | - | - | - | - | - | - | - |
EBITDA |
-192 M | -215 M | -18.8 M | 582 M | 561 M | 125 M | 48.1 M | 38.8 M | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | 52.3 M | 46.6 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
145 M | 162 M | 151 M | 129 M | 100 M | 94.2 M | 48.4 M | 41.2 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Maravai LifeSciences Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
148 M | 146 M | 145 M | 144 M | 143 M | 142 M | 136 M | 132 M | 132 M | 132 M | 132 M | - | 132 M | 132 M | 131 M | - | 118 M | 112 M | 96.6 M | - | 254 M | 254 M | 254 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-12.4 M | -3.73 M | -25.6 M | -39.6 M | -29.9 M | -97.1 M | -9.79 M | -12.1 M | -6.46 M | -6.54 M | -67 K | - | 44.5 M | 71.2 M | 66.9 M | - | 54.3 M | 49.1 M | 23.1 M | 11.4 M | 39 M | 1.42 M | 23.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
51.4 M | 65.8 M | 41.6 M | 47.4 M | 46.8 M | 69 M | 69.4 M | 64.2 M | 66.9 M | 68.9 M | 79 M | - | 191 M | 243 M | 244 M | - | 205 M | 218 M | 148 M | - | 87.9 M | 46.9 M | 51 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
30.8 M | 32.1 M | 36 M | 39.6 M | 39.1 M | 36.8 M | 38.6 M | 38.3 M | 36.7 M | 43.3 M | 33.7 M | - | 38.2 M | 37.5 M | 40 M | - | 32 M | 37.5 M | 31.4 M | - | 19.8 M | 21.2 M | 15.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
20.6 M | 33.7 M | 5.66 M | - | - | 32.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-15.1 M | -2.16 M | -41 M | -66.3 M | -49.2 M | -166 M | -13.4 M | -18.9 M | -15.4 M | -11.6 M | 2.53 M | - | 117 M | 181 M | 167 M | - | 157 M | 154 M | 91.2 M | - | 45.7 M | 8.12 M | 34.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-52 K | -494 K | -71 K | -4.06 M | 24 K | 72 K | -2.56 M | 10.9 M | 11.6 M | 7.02 M | 11.8 M | - | 3.14 M | 4.43 M | 2.66 M | - | 8.54 M | 8.51 M | 7.9 M | - | 7.09 M | 7.46 M | 7.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-9.78 M | 2.74 M | -35.1 M | -60.3 M | -43.5 M | -161 M | -7.88 M | -14.1 M | -11.3 M | -8.8 M | 4.61 M | - | 119 M | 183 M | 169 M | - | 159 M | 157 M | 92.4 M | - | 47.4 M | 9.55 M | 36.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
32.1 M | 29.1 M | 35.4 M | 38.6 M | 39.6 M | 39.1 M | 40.6 M | 40.9 M | 38.9 M | 35.4 M | 38.7 M | - | 30.8 M | 28.1 M | 33.2 M | - | 25.2 M | 24.1 M | 23.5 M | - | 20.5 M | 16 M | 16.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Maravai LifeSciences Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Singapore
Irlanda
Britain
Israel
